Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of HS (confirmed by a dermatologist) with a disease duration of at least 6 months before screening.~* Stable course of HS for at least 90 days before screening, as determined by the investigator.~* HS lesions present in at least 2 distinct anatomic areas, 1 of which must be Hurley Stage II or III at screening and baseline.~* Total AN count of at least 3 at screening and baseline.~* Male participants must agree to use contraception per protocol-defined criteria.~Exclusion Criteria:~* Women of childbearing potential or who are currently pregnant or lactating.~* Presence of \> 20 draining fistulas at screening and baseline.~* Participants with concurrent conditions or history of other diseases as follows:~  * Any clinically significant medical condition other than HS, as determined by the investigator, that is not adequately controlled with appropriate treatment.~ * Any other active skin disease or condition (eg, bacterial, fungal, or viral infection) that may interfere with the course, severity, or assessments of HS.~ * Active systemic viral infection or any active viral infection that, based on the investigator's clinical assessment, make the participant an unsuitable candidate for the study.~ * Current herpes zoster infection, a history of recurrent herpes zoster, a history of disseminated herpes simplex, or a history of herpes zoster.~ * History of malignancy, including lymphoma and leukemia within 5 years before baseline, other than a successfully treated nonmetastatic cutaneous squamous cell carcinoma, basal cell carcinoma, or localized carcinoma in situ of the cervix.~ * Albinism.~* Prolonged QT interval corrected for heart rate using Fridericia's formula (QTcF), defined as ≥ 450 msec.~* Positive test result for tuberculosis (TB) from the QuantiFERON-TB Gold test, or equivalent, at screening (or, if 2 indeterminate tests or not available, then as evaluated by a purified protein derivative test with a result of \< 5 mm of induration within 3 months of screening) or a history of active TB.~* Positive serology test results for HIV, HBsAg, hepatitis B virus (HBV) core antibody, or HCV (HCV antibody with positive HCV-RNA) at screening.~* Decreased blood cell counts at screening as per protocol-defined parameters.~* Severely impaired liver function (Child-Pugh Class C) or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels ≥ 1.5 × upper limit of normal (ULN).~* Impaired renal function with serum creatinine \> 1.5 mg/dL.~* Use of prohibited medications per protocol-defined criteria.~* Known or suspected allergy to INCB054707 or any component of the study drug.~* Known history of clinically significant drug or alcohol abuse in the last year prior to baseline.~* Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- INCB054707 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).